ALSO READUnichem Labs gets USFDA nod for migraine tablets Unichem Lab shares tank over 6.5% on disappointing Q2 results Unichem Labs Q2 net slips 11 pc at Rs 20.52 cr Unichem Laboratories standalone net profit declines 11.28% in the September 2016 quarter Board of Unichem Laboratories to consider Q3 and 9M results
Drug firm Unichem Laboratories today said it has received approval from the US health regulator for Piroxicam Capsules, used in treatment of osteoarthritis and rheumatoid arthritis, in the US market.
In a BSE filing, Unichem Laboratories said "it has received ANDA approval from the United States Food and Drug Administration (USFDA) for Piroxicam Capsules USP 10mg and 20mg".
The approved product is therapeutically equivalent to Feldene Capsules 10mg and 20mg of Pfizer Inc.
Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA).
Unichem Laboratories said the product will be commercialised from its Goa plant.
"Active Pharmaceutical Ingredient will also be made in-house at Roha API Plant," it added.
Shares of Unichem Laboratories were trading 1.49 per cent higher at Rs 290 on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)